House of Lords written question – answered at on 12 February 2013.
To ask Her Majesty's Government whether they will approve the use of eculizumab for the treatment of atypical haemolytic uraemic syndrome.
The Advisory Group for National Specialised Services (AGNSS) undertook an assessment of the drug eculizumab for the treatment of atypical haemolytic uraemic syndrome (aHUS) for possible inclusion in national specialised commissioning arrangements. The Government accepted the advice of AGNSS on the clinical effectiveness of the drug in treating aHUS but wanted further advice on its suitability for direct commissioning taking account of its cost, benefit and affordability.
The Government have asked the National Institute for Health and Clinical Excellence to develop guidance on the use of eculizumab in its treatment of aHUS as the first topic in its new highly specialised technologies programme.
Yes0 people think so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.